| abstract |
The present invention relates to novel 2-substituted-4,5-diaryl-imidazoles which have i) the N-position substituted with a trialkylsilyl substituent, or ii) the 2-position substituted with arylalkyl, arylsulfonyl, aryl; thio-, aryl-seleno-, aryl-telluro-, cycloalkyl-, cycloalkenyl-, alkyl-cycloalkyl-, alkyl- cycloalkenyl-, amino- or hydrazino- or mono- or bicyclic N-heterocyclic groups in which the nitrogen-containing ring is in particular, the six-membered compound relates to the compounds of formula (I) in free form or in the form of a pharmaceutically acceptable acid addition salt or a physiologically cleavable ester; The compounds have inhibitory activity against p38 MAP kinase (Mitogen activated protein kinase). The compounds as drugs are TNFα and IL-1 mediated diseases, e.g. rheumatoid arthritis and bone metabolism disorders, e.g. can be used to treat osteoporosis. HE |